(Boursier.com) — Valbiotis clarified its commercial roadmap
and clinical for 2024, a year which will be marked by several major strategic milestones with, in the first half of the year, the launch of the marketing of the plant substance TOTUM 070 against hypercholesterolemia on the French market as well as the first order from Nestlé Health Science in TOTUM 63.
To honor this and secure the TOTUM 63 production chain over the long term, Valbiotis announces that industrial activities are already in working order, with the constitution of the first strategic stocks, the qualification of industrial partners making the subject to high and controlled certifications, as well as validation of processes on an industrial scale.
These structuring efforts will be strengthened in 2024 with a view to also supporting future licensing and/or distribution partnerships for the international marketing – outside of France – of other food supplements: TOTUM 070 (hypercholesterolemia), TOTUM 854 (hypertension arterial) and TOTUM 448 (metabolic liver diseases). For these three products, the objective remains the signing of one or more agreements at global or regional level. Thus, Business Development activities are continuing at the start of the year. Among the 68 prospects identified, discussions are underway with several major players in nutrition or health.
The latest key strategic milestone, the direct marketing by Valbiotis of its products in France (excluding TOTUM 63) will begin in the first half of 2024 with the launch of TOTUM 070. The structuring for this launch is already described as very advanced, both in terms of industrial processes, IT infrastructure (enlargement of the ERP, construction of the e-commerce platform) or sales and marketing policy. The latter will rely on a dedicated team of medical promotion officers (APM) whose recruitment has already begun, targeting prescribing doctors and key pharmacies, and will be supplemented by a direct approach to patients via an appropriate digital strategy.
Valbiotis will also continue its R&D efforts to consolidate the high level of scientific proof of its portfolio in the prevention of metabolic and cardiovascular diseases, and to prepare the pipeline of tomorrow. After the complete journey carried out by TOTUM 63, the ambition remains to successfully complete the clinical processes on the three other products and to obtain health claims – without these steps constituting a prerequisite for their marketing. On this scientific front, several key milestones are also expected in 2024.
©2024 Boursier.com